Acenocoumarol
- Atc Codes:B01AA07
- CAS Codes:152-72-7
- PHARMGKB ID:152-72-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Caution and personalized dose adjustment in patients with the following genotypes
- Other genes that may be involved
- Substrate of
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Sintrom; Belgium: Sintrom; Bulgaria: Acenocoumarol, Sintrom; France: Minisintrom, Sintrom; Greece: Sintrom; Hungary: Syncumar; Italy: Sintrom; Lithuania: Acenocumarol; Luxembourg: Sintrom; Netherlands: Acenocoumarol; Poland: Acenocoumarol, Acenocumarol, Sintrom, Syncumar; Portugal: Sintrom; Romania: Acenocumarol, Sintrom, Trombostop; Spain: Sintrom; UK: Sinthrome.
North America
Canada: Sintrom.
Latin America
Argentina: Acenocoumarol, Acenocumarol, Acenotromb, Antitrom, Azecar, Fortonol, Saxion, Sintrom; Mexico: Sintrom.
Drug combinations
Chemistry
Acenocoumarol: C~19~H~15~NO~6~. Mw: 353.33. (1) 2H-1-Benzopyran-2-one, 4-hydroxy-3-[1-(4-nitrophenyl)-3-oxobutyl]-; (2) 3-(α-Acetonyl-p-nitrobenzyl)-4-hydroxycoumarin. CAS-152-72-7.
Pharmacologic Category
Antithrombotic Agents; Anticoagulants; Coumarin Derivatives; Vitamin K Antagonists. (ATC-Code: B01AA07).
Mechanism of action
Interferes with hepatic synthesis of vitamin K-dependent coagulation factors (II, VII, IX, X).
Therapeutic use
Prophylaxis and treatment of venous thrombosis, pulmonary embolism and thromboembolic disorders. Atrial fibrillation with risk of embolism. Prophylaxis of coronary occlusion and transient ischemic attacks.
Pregnancy and lactiation implications
Avoid use during pregnancy (significant risks). Not recommended during lactation.
Unlabeled use
Contraindications
Hypersensitivity to acenocoumarol or any component of the formulation. Hemorrhagic tendencies. Hemophilia. Thrombocytopenic purpura. Leukemia. Recent or potential surgery of the eye or CNS. Major regional lumbar block anesthesia or surgery resulting in large, open surfaces. Bleeding from the gastrointestinal, respiratory, or genitourinary tract. Threatened abortion. Aneurysm. Prolonged dietary insufficiencies (vitamin K deficiency). Ascorbic acid deficiency. History of bleeding diathesis. Prostatectomy. Continuous tube drainage of the small intestine. Polyarthritis. Diverticulitis. Emaciation. Malnutrition. Cerebrovascular hemorrhage. Eclampsia/pre-eclampsia. Blood dyscrasias. Severe uncontrolled or malignant hypertension. Severe hepatic disease. Pericarditis or pericardial effusion. Subacute bacterial endocarditis. Visceral carcinoma. Following spinal puncture and other diagnostic or therapeutic procedures with potential for significant bleeding. History of warfarin-induced necrosis. Alcoholism. Patient with significant fall risk. Pregnancy.
Warnings and precautions
May cause hypersensitivity reactions (use with caution in anaphylactic disorders). Risk of major or fatal bleeding. Necrosis or gangrene of skin and other tissues (due to early hypercoagulability) might occur (rarely). «Purple toe» syndrome (due to cholesterol microembolization) has been described with coumarin-type anticoagulants. Caution in acute infection or active tuberculosis (antibiotics and fever may alter response to the drug), renal impairment or thyroid disease. The elderly may be more sensitive to anticoagulant therapy. Ovulating women may be at risk of developing ovarian hemorrhage at the time of ovulation.